Drug reference
meropenem-vaborbactam
Carbapenem–β-lactamase inhibitor combination · Antibacterial; Carbapenem/β-Lactamase Inhibitor
Carbapenem–β-lactamase inhibitor combinationAntibacterial; Carbapenem/β-Lactamase Inhibitor
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Meropenem inhibits bacterial cell-wall synthesis. Vaborbactam inhibits AmpC β-lactamases, ESBLs, and KPCs, but not metallo-carbapenemases (e.g., NDM).
Side effects
Common
Gastrointestinal side effects (e.g., diarrhea)
Serious
- Hypersensitivity reactions (rash to anaphylaxis)
- Serum sickness
- Stevens-Johnson syndrome
- Nephropathy
- Hematologic reactions (neutropenia, prolonged use)
- Neurotoxicity (seizure, high doses, renal impairment)
Related guidelines
Other Carbapenem–β-lactamase inhibitor combination drugs
Ask House about meropenem-vaborbactam
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Harrison 22e·Verified: 2026-05-10 · House clinical team